NEW YORK, Dec. 13 – Aventis has subscribed to a selection of samples in Gene Logic’s database, Gene Logic said Thursday.
Under the terms of the deal, Aventis will have access to samples culled from Gene Logic’s BioExpress database. The BioExpress database contains gene expression information for normal and diseased human tissues, tissues from model animal systems, and human and animal cell lines for use in drug target identification.
Gene Logic said the deal for its CustomSuite, a customized database product, would give Aventis data directly applicable to the pharmaceutical company’s drug development projects.
In addition, Gene Logic will generate data for Aventis based on samples it provides to Gene Logic.
Gene Logic did not disclose the financial terms of the deal, its first with Aventis.
Aventis Pharmaceuticals is the U.S. division of Aventis Pharma of Frankfurt.